WHO Raises Alert Over Critical Lack of Obesity Medications
Under 10% of patients who could benefit from GLP-1 drugs like Wegovy are able to get them, states the WHO as it issues its initial advice on the drugs.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for broader and more equitable access to GLP-1 medication.
According to projections, over two billion could be living with obesity by 2030 without intervention.
"Our new guidance affirms that excess weight is a long-term condition that can be treated with thorough and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major obstacles to broad access to the jabs that can aid individuals in losing considerable weight, notes the organization.
Weight-Loss Drug Supply Crisis
Despite the present most optimistic case, the supply of these medications would only suffice for about 100 million people – less than 10% of eligible patients, as stated by the health organization.
The advice encourages countries and companies to expand access, by approaches like voluntary licensing.
A patent on a key compound – the main ingredient of Novo Nordisk's Wegovy – is due to expire in several countries in 2026.
The Way Weight-Loss Drugs Work
The injections mimick a body's own hormone to slow digestion, suppress the appetite and increase satiety so individuals reduce food intake.
Patients typically begin shedding pounds within a few weeks of commencing the once-weekly jabs.
Research indicates people may regain a significant portion after a year of discontinuing the treatment, because their usual appetite return.
To be above a healthy weight elevates your chance for contracting medical conditions, such as type 2 diabetes, heart disease, stroke, and certain cancers.
Excess weight impacts individuals in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
